Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14677MR)

This product GTTS-WQ14677MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in B cell lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14677MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14883MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ2814MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG-301
GTTS-WQ736MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AAB-001
GTTS-WQ6468MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CT-P-59
GTTS-WQ14085MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-421
GTTS-WQ3656MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ7260MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FP3 protein
GTTS-WQ14301MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RG-7221
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW